无水滴眼环孢素制剂治疗干眼症的II期临床研究
结果显示CyclASol在角膜和结膜染色方面较赋形剂和Restasis有一致性改善,起效早至第14天,安全性和耐受性良好。
要点
- CyclASol在角膜和结膜染色方面较赋形剂和Restasis有一致性改善,起效早至第14天。
- 混合效应模型显示CyclASol对总角膜染色P<0.1、中央角膜染色P<0.001、结膜染色P<0.01。
- CyclASol对OSDI症状参数也有显著效果(P<0.01),各治疗组眼部不良事件数量均较低。
核心结论
- CyclASol两种浓度在中等至重度干眼症中显示出疗效、安全性和耐受性。
- 与开放标签Restasis直接比较,CyclASol起效更早,最早在治疗2周后即改善干眼体征(角膜和结膜染色)。
- 中央角膜区域(干眼患者视觉功能重要区域)从治疗中获益最大。
- 良好的安全性、耐受性和舒适性支持该新型环孢素制剂具有正向获益-风险比。
研究设计与样本
- 探索性II期、多中心、随机、赋形剂对照临床试验,CyclASol与赋形剂双盲,开放标签对照药。
- 经过2周导入期(每日两次Systane Balance)后,患者随机进入相应治疗组,每日两次用药16周。
主要发现
- CyclASol在16周治疗期间较赋形剂和Restasis一致性地降低角膜和结膜染色,起效早至第14天。
- 混合效应模型分析显示CyclASol对总角膜染色(P<0.1)、中央角膜染色(P<0.001)、结膜染色(P<0.01)的药物效应有统计学意义。
- 基于模型的分析提示CyclASol对症状参数OSDI有显著效应(P<0.01)。
- 所有治疗组眼部不良事件数量均较低。
关键数值与推荐
- 主要结局指标包括总角膜染色和分区角膜染色、结膜染色、干眼症状视觉模拟量表(VAS)严重程度和眼表疾病指数(OSDI)问卷。
- CyclASol对总角膜染色的药物效应P<0.1,中央角膜染色P<0.001,结膜染色P<0.01,OSDI P<0.01。
临床怎么用
- CyclASol可能为中等至重度干眼症提供一种起效快、安全性好的环孢素治疗选择。
- 中央角膜染色改善提示对视觉功能相关区域有潜在获益。
局限性
- Restasis为开放标签对照,非双盲比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare the efficacy, safety, and tolerability of waterfree cyclosporine formulation (CyclASol) at 2 concentrations (0.1% and 0.05% of cyclosporine [CsA]) to vehicle when applied twice daily for 16 weeks in patients with dry eye disease (DED). An open-label Restasis (Allergan, Irvine, CA) arm was included to allow a direct comparison with an approved therapy. DESIGN: An exploratory phase II, multicenter, randomized, vehicle-controlled clinical trial, double-masked between CyclASol and vehicle with an open-label comparator. PARTICIPANTS: Two hundred and seven eligible patients with a history of dry eye disease were randomized 1:1:1:1 to 1 of 4 treatment arms (CyclASol 0.05%, n = 51; CyclASol 0.1%, n = 51; vehicle, n = 52, and Restasis, n = 53). METHODS: After a 2-week run-in period with twice-daily dosing of Systane Balance (Alcon, Fort Worth, TX), patients were randomized to the respective treatment arm and dosed twice daily for 16 weeks. MAIN OUTCOME MEASURES: The study was set up to explore efficacy on a number of sign and symptom end points including total and subregion corneal fluorescein staining, conjunctival staining, visual analog scale (VAS) for dry eye symptoms VAS severity, and Ocular Surface Disease Index (OSDI) questionnaire. RESULTS: CyclASol showed a consistent reduction in corneal and conjunctival staining compared with both vehicle and Restasis over the 16-week treatment period, with an early onset of effect (at day 14). A mixed-effects model-based approach demonstrated that the CyclASol drug effect was statistically significant over vehicle (total corneal staining P < 0.1, central corneal staining P < 0.001, conjunctival staining P < 0.01). This model-based analysis suggests a significant CyclASol effect for OSDI as symptom parameter (P < 0.01). The numbers of ocular adverse events were low in all treatment groups. CONCLUSIONS: CyclASol showed efficacy, safety, and tolerability at 2 concentrations in moderate-to-severe DED. In a direct head-to-head against open-label Restasis, CyclASol was found to have an earlier onset of action, as early as after 2 weeks of treatment, in relieving the signs of DED, as measured by corneal and conjunctival staining. The central region of the cornea, an important area for visual function in dry eye sufferers, was shown to have the most benefit from treatment. Excellent safety, tolerability, and comfort profile supports this new CsA formulation as having a positive benefit-to-risk ratio.
引用
- Wirta DL, Torkildsen GL, Moreira HR, et al. A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease. Ophthalmology. 2019. PMID: 30703441. doi:10.1016/j.ophtha.2019.01.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。